IMGN
$4.05
Immunogen
$.11
2.79%
IMGN
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.19)
Revenue:  N/A
Friday
Oct 30
6:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when IMGN reports earnings?
Beat
Meet
Miss

Where is IMGN's stock price going from here?
Up
Flat
Down
Stock chart of IMGN
Analysts
Summary of analysts' recommendations for IMGN
Score
Grade
Pivots
Resistance
$4.43
$4.28
$4.17

$4.02

Support
$3.91
$3.76
$3.65
Tweet
Growth
Description
ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The company's product candidates are called tumor-activated prodrugs and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, tumor-activated prodrugs are intended to deliver potent chemotherapy specifically to a tumor. Each tumor-activated drug immunoconjugate comprises a small-molecule drug which has been chemically linked to a monoclonal antibody.
Peers
InterCeptRegeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalJohnson & JohnsonZoetisBristol-Myers SquibbUltragenyx PharmaceuticalCatalentMerck & Co.